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Triggering TLR7 in mice induces immune activation and
lymphoid system disruption, resembling HIV-mediated
pathology
Abstract
Chronic immune activation is a major cause for progressive immunodeficiency in human
immunodeficiency virus type-1 (HIV) infection. The underlying trigger, however, remains largely
unknown. HIV single-stranded RNA is a potent immune activator by triggering Toll-like receptor (TLR)
7/8. Thus, we hypothesized that sustained TLR7 triggering induces chronic immune activation and
thereby contributes to progressive immunodeficiency. We used the synthetic compound R848 or a
mixture of uridine-rich HIV single-stranded (ss) RNA oligonucleotides - both are potent TLR7/8
agonists - to explore the effects of sustained TLR7 triggering on the murine lymphoid system. Sustained
TLR7 triggering induced an immunopathology reminiscent of progressive lymphoid destruction in HIV
disease; we observed lymphopenia, elevated proinflammatory cytokines, splenomegaly, contracted
lymphoid subsets, and lymphoid microarchitecture alteration with reduced marginal zone
B-lymphocytes. Upon exposure to inactivated vesiculo-stomatitis virus, antibody production was
abolished, although splenic lymphocytes were activated and total IgG was elevated. Our data imply that
HIV itself may directly contribute to immune activation and dysfunction by stimulating TLR7. Thus,
manipulation of TLR7 signalling may be a potential strategy to reduce chronic hyper-immune activation
and, thereby, disease progression in HIV infection.
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Abstract 
Chronic immune activation is a major cause for progressive immunodeficiency in human 
immunodeficiency virus type-1 (HIV) infection. The underlying trigger, however, 
remains largely unknown. HIV single-stranded RNA is a potent immune activator by 
triggering Toll-like receptor (TLR) 7/8. Thus, we hypothesized that sustained TLR7 
triggering induces chronic immune activation and thereby contributes to progressive 
immunodeficiency. We used the synthetic compound R848 or a mixture of uridine-rich 
HIV single-stranded (ss) RNA oligonucleotides – both are potent TLR7/8 agonists - to 
explore the effects of sustained TLR7 triggering on the murine lymphoid system. 
Sustained TLR7 triggering induced an immunopathology reminiscent of progressive 
lymphoid destruction in HIV disease; we observed lymphopenia, elevated 
proinflammatory cytokines, splenomegaly, contracted lymphoid subsets, and lymphoid 
microarchitecture alteration with reduced marginal zone B-lymphocytes. Upon exposure 
to inactivated vesiculo-stomatitis virus, antibody production was abolished, although 
splenic lymphocytes were activated and total IgG was elevated. Our data imply that HIV 
itself may directly contribute to immune activation and dysfunction by stimulating TLR7. 
Thus, manipulation of TLR7 signalling may be a potential strategy to reduce chronic 
hyper-immune activation and, thereby, disease progression in HIV infection. 
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Introduction 
Progressive CD4+ T-cell depletion and chronic immune activation are hallmarks of HIV 
infection. Chronic immune activation includes aberrant cytokine production, 
redistribution of lymphocyte subpopulations, polyclonal B-cell activation, increased T-
cell turnover, and increased numbers of activated T cells.  
Several observations suggest a crucial role of chronic immune activation in HIV 
pathogenesis. i) Increased numbers of activated CD4+ T cells expressing the activation 
markers CD69, CD25, and MHC class II and activated CD8+ T cells expressing the 
activation marker CD38 correlate with HIV disease progression and CD4+ T-cell loss in 
untreated infection1. ii) Immune activation is absent in non-pathogenic simian 
immunodeficiency virus (SIV) infection. In particular, the natural hosts of SIV, sooty 
mangabeys and African green monkeys, show only minimal increases in immune 
activation and rarely progress to immunodeficiency despite high levels of viral 
replication2. iii) Immune activation facilitates HIV infection of T cells by promoting co-
receptor, adhesion molecule, and nuclear factor (NF)-κB expression3-5. iv) Persistent 
immune activation in mice that constitutively express CD70 can induce lethal T-cell 
immunodeficiency6.  
The precise mechanism and underlying trigger by which HIV causes immune 
activation remain poorly understood: Schindler and colleagues7 noted that Nef from 
nonpathogenic SIV strains mediated downmodulation of the host T-cell receptor and 
thereby suppressed T-cell activation, whereas Nef from HIV did not. This hypothesis 
remains controversial when considering that only a small fraction of cells are infected 
while a general immune activation is present8. Alternatively, T-cell recognition of HIV 
antigens, gp120- and Nef-mediated signaling9,10, and regulatory CD4+ T-cell depletion11 
have also been proposed as major contributors to immune activation.  
TLRs belong to the family of pattern recognition receptors, are essential in innate 
immunity in mammals by recognizing conserved patterns of microorganisms (PAMP), 
are selectively expressed on cells of the immune system, and subsequent to their ligation 
induce a complex signaling resulting in anti-microbial activity12. Sustained TLR 
triggering by circulating microbial products (TLR4 ligands), likely derived from the 
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gastrointestinal tract through breaks in the mucosal barrier, was recently proposed as a 
cause of HIV-related systemic immune activation13.  
Immune activation correlates with HIV viremia and declines rapidly after initiation of 
HAART, long before peripheral CD4+ T-cell recovery14. These observations suggest a 
direct role for viral replication products in immune activation. In this context, HIV 
ssRNA is likely to contribute directly to immune activation: human TLR7/8 and murine 
TLR7 recognize HIV ssRNA and trigger the corresponding signaling pathway14-16. 
Importantly, the HIV genome encodes for multiple potent TLR7/8 ligands14. Moreover, 
chronic, untreated HIV infection is associated with increased TLR7 responsiveness and 
expression, which correlates with plasma HIV-RNA load17. Funderburg et al. recently 
proposed that systemic exposure to microbial TLR agonists (i.e., HIV ssRNA and 
bacterial LPS and DNA translocated from the damaged gut) may drive immune 
dysfunction in chronic HIV infection18.  
In natural HIV infection, the immune system fails to eliminate the virus, resulting in 
persistent virion and thus ssRNA production although only a minor fraction of these 
virions (i.e., 1/60,000) is infectious.   
Here we hypothesized that sustained immune activation through TLR7/8 is a main 
driver for chronic immune activation and thereby contributes to the progressive 
immunodeficiency observed in HIV infection. To explore the effects of sustained TLR7 
triggering on the molecular and cellular components of the lymphoid system of mice, we 
used the synthetic compound R848 or HIV ssRNA oligonucleotides. R848 triggers 
TLR7/8 in a manner similar to HIV ssRNA14,15,19. While there are cross-species 
differences in TLR7/8 triggering in human vs. mice such as the lack of triggering murine 
TLR8 by R848 or HIV ssRNA15,20,21, the main function of TLR7 triggering is common in 
both species, e.g., DC activation and induction of IFN-α20. Thus, irrespective of 
differences in TLR signaling, we consider the mouse valid for examining our hypothesis. 
We demonstrate here that chronic triggering of TLR7 in mice results in immune 
activation, functional impairment and disruption of the lymphoid system reminiscent of 
HIV-associated pathology. 
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Material and Methods 
 
Mice and treatment 
C57BL/6 mice were purchased from Harlan (The Netherlands). Interferon receptor 
(IFNAR)-/- and TLR7-/- mice22,23 were kindly provided by Karl S. Lang (Institute of 
Experimental Immunology, University Hospital of Zurich, Switzerland). Interferon 
regulatory factor (IRF) 7-/- mice24 were provided by Kenya Honda. MyD88-/- mice25 
were obtained through the Swiss Immunological Mutant Mouse Repository (Zurich, 
Switzerland). All procedures were approved by the veterinarian authorities from the 
Canton of Zurich, Switzerland. 
Age- and sex-matched mice (6–8 weeks) were injected intraperitoneally (i.p.) for 7 
days with 0.01, 0.1, or 1 mg/kg/day R848 and for 21 or 42 days with 0.01 or 0.1 
mg/kg/day R848. Control mice were treated with 50 µg/mouse/day polyinosinic-
polycytidylic acid (polyI:C, Sigma, St. Louis, USA) or with PBS. R848 was kindly 
provided by 3M Pharmaceuticals. Substances were dissolved in PBS and administered 
i.p. at 200 µl/dose. Mice were analyzed 1 h after the last injection unless otherwise stated.  
HIV ssRNA application: mice were injected intravenously (i.v.) with 50 µg synthetic, 
phosphothioate modified, uridine-rich HIV ssRNA (a mixture of Gag1166-1185, 
VIF327-346, VPR203-222, GP160 2093-211214, and RNA4015; 10 µg each) or control 
ssRNA (A variants14 and RNA4115) which were complexed to 50 µl DOTAP (Roche, 
Basel, Switzerland). 
 
Quantification of peripheral blood leukocytes 
Blood samples were collected in heparinized microtainers (BD Biosciences) by terminal 
bleeding from the heart. Absolute and relative numbers of leukocytes, lymphocytes, 
monocytes, neutrophils, and thrombocytes were quantified on an Abbott Zelldyn 3500 or 
counted manually after staining on Hematec (Bayer, Tarrytown, USA) at the 
veterinarian-medical hospital, Zurich, Switzerland.  
 
 
 
Page 5/34 
Flow cytometry 
Absolute counts of lymphocyte subpopulations were determined by BD truCOUNT 
technology and by staining the samples for CD4 (clone L3T4), CD8 (Ly-2), and B220 
(RA3-6B2), according to the manufacturer’s protocol. The activation status of the 
splenocytes was analyzed by four-color flow cytometry with monoclonal antibodies 
against CD4, CD8, B220, and CD69 (H1.2F3) after lysis of erythrocytes with ACK lysis 
buffer. Similarly, frequencies of myeloid cells in spleen were determined by staining for 
CD11b (M1/70), CD11c (HL3), and/or Gr-1 (RB6-8C5). Splenic germinal center B-cell 
frequencies were evaluated by staining for B220 in conjunction with FITC-labeled peanut 
agglutinin (PNA; Vector Laboratories, Burlingame, USA) or GL7 antibody. Relative cell 
numbers in thymocyte subsets were measured by staining for CD4 and CD8. Antibodies 
were from BD PharMingen (Heidelberg, Germany). Cells were acquired on a FACS 
Calibur (BD Biosciences). Data were analyzed with FlowJo 7.1 software. 
 
VSV-specific serum neutralization test and determination of total IgG 
Before injection in mice, vesicular stomatitis virus (VSV; Mudd-Summers isolate) was 
ultraviolet-inactivated (UV Stratalinker 1800; Stratagene) for 5 min in an open 60-mm 
Petri dish. Titers of VSV neutralizing antibodies in sera were determined as described 
before26. Total IgG was quantified with mouse IgG ELISA quantification kit (Bethyl 
Laboratories), according to the manufacturer’s instructions. 
 
Histology and immunohistochemistry 
Spleens were stored in HBSS and flash frozen in liquid nitrogen for immunohistological 
analysis. Frozen spleen sections (6 µm) were stained with H&E. Antibodies FDC-M1 
(4C11; 1:50, Becton Dickinson) and CD21/35 (8C12; 1:100; PharMingen) and antibodies 
to CD45RO/B220 (RA3-6B2; 1:400; PharMingen), MOMA-1 (1:50; BMA; Augst), 
F4/80 (1:50; Serotec), PNA (1:100; Vector Laboratories), CD4 (YTS 191; 1:200), and 
CD8 (YTS 169; 1:50) were used as primary reagents for immunohistochemistry and 
lectin histochemistry, as described27. Antibodies against CD4 and CD8 were kindly 
provided by R. Zinkernagel (University Hospital of Zurich, Switzerland). Image 
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acquisition was performed on an Axiophot-microscope (Zeiss) equipped with a JVC 
digital camera (KY-F70; 3CCD) and analyzed with their software. 
 
Measurement of serum cytokines 
Mouse blood was collected into serum separator microtubes (BD Biosciences) and 
centrifuged for 10 min at 5,400 g. Cytokine levels in serum were measured using a 
multiplexed particle-based flow cytometric cytokine assay. Bioplex mouse kits were 
purchased from BioRad. The analysis was conducted using FC 500 flow cytometer 
(BeckmanCoulter). 
 
Statistical analyses 
Data are depicted as means and SEM. Means were compared using the unpaired t-test, 
unless otherwise stated (* p<0.05, ** p<0.01, *** p<0.001, ns = not significant). 95% 
confidence intervals of normalized data were computed using graph pad software, 
according to EC Fieller28. 
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Results 
Sustained TLR7 stimulation resulted in lymphopenia and increased neutrophil and 
monocyte numbers 
To assess the effects of sustained TLR7 triggering in vivo, C57BL/6 mice were treated 
with R848 daily for up to 42 days. We sought to replicate the persistent nature of HIV 
infection with sustained exposure of lymphoid tissue to the HIV ssRNA burden.  
Mice treated with R848 showed no loss of body weight or signs of overt toxicity: 
liver enzymes and markers of renal, hepatic, cardiac, and pancreatic functions remained 
the same as those in PBS-treated control mice (data not shown). In general, no or only 
minor blood-parameter changes were observed at the lowest dose of 0.01 mg/kg/d R848, 
whereas pronounced effects were observed at 0.1 and 1 mg/kg/d R848. At neither dose 
did TLR7 triggering alter the absolute numbers of circulating leukocytes as determined 
by flow cytometry (Fig. 1A, left) and by an automatic hemocounter (Fig. 1A, right). 
Similar data were observed when mice were given a single dose and analyzed after 30, 
90, and 180 min (data not shown) in contrast to recently reported data29.  
Total lymphocytes and all major lymphocytic cellular subsets (i.e., B220+, CD4+, and 
CD8+ cells) were significantly decreased after 7 days of TLR7 triggering in a dose-
dependent fashion (Fig. 1B). In contrast, absolute and relative monocyte and neutrophil 
numbers dramatically increased (Fig. 1A, C and data not shown). Blood from R848-
treated mice also showed a tendency towards reduced thrombocyte counts (Fig. 1D), 
which is frequently associated with HIV infection30. The detected changes in blood are 
specific for TLR7 and not a universal phenomenon in response to triggering TLRs, since 
equivalent triggering of TLR3 by its ligand polyI:C did not lead to changes in any of the 
above described parameters. The observed effects were nearly abolished in TLR7-/- mice. 
In contrast, type I interferon-mediated signaling via IFNAR and IRF7 signaling seemed 
not to be critically involved, since changes in white blood cell counts were similar in 
R848 vs. mock treated IFNAR-/-, IRF7-/-, or C57BL/6 mice (Suppl. Fig. 1).  
We next addressed whether chronic TLR7 triggering with low doses over a longer 
time would have the same effect as the 7-day high-dose regimen. Treatment with R848 
for 21 and 42 days induced similar effects. Minor effects were detected at the lowest dose 
of 0.01 mg/kg/d, while profound lymphopenia and increased neutrophil and monocyte 
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numbers were seen at the 10-fold dose (Fig. 1E and not shown). In conclusion, sustained 
triggering of TLR7 dramatically alters white blood cell counts, including profound 
lymphopenia and increased neutrophil and monocyte levels.  
 
Reduced antigen-specific humoral immune response and immune activation  
Defective humoral immunity is a hallmark of HIV infection31. We sought to determine 
the effect of chronic TLR7 activation on humoral immune responses. After 7 days of 
R848 treatment (1 mg/kg/d), mice were immunized i.v. with 1x106 plaque forming units 
(PFU) of ultraviolet-inactivated VSV (UV-VSV). Antigen exposure is a major 
determinant for a subsequent VSV-specific humoral immune response. Since the milieu 
generated by sustained triggering of TLR7 may affect the strength of VSV replication 
and thus the antigen exposure, we used inactivated VSV that guaranteed the same 
antigen-load in the mock- and R848-treated mice. All mice showed an IgM-IgG class 
switch between day 3 and 7 after immunization (Fig. 2A). However, triggering TLR7 
caused reduced IgM titers at day 3 after UV-VSV challenge and a striking reduction in 
immunoglobulin class switch with very low IgG titers 7 and 10 days after UV-VSV 
challenge. Thereafter, IgG titers slowly recovered, perhaps because stopping R848 
treatment upon immunization led to gradual reversion of TLR7-mediated effects and 
because antigen was gradually released from its local depot. Nonetheless, VSV-specific 
IgG titers were still slightly lower 20 days after immunization. 
B-cell activation, with the consequent hypergammaglobulinaemia, is one of the most 
characteristic features of the intricate immune impairment observed in HIV infection31. 
This phenomenon involves all immunoglobulin subclasses and results in the augmented 
production of HIV-specific and, mostly, HIV-unrelated antibodies. By contrast, chronic 
hyper-activation of B lymphocytes could lead to B-cell exhaustion or anergy and to 
concomitant low levels of immunoglobulin. We thus tested whether sustained triggering 
of TLR7 affected total IgG levels. UV-VSV inoculation and subsequent antibody 
response resulted in a twofold increase of total IgG on day 20 after immunization in both 
mock- and R848-treated mice (Fig. 2B). Strikingly, total IgG levels were increased by 
approximately 50% in R848-treated mice as compared to mock-treated mice after 7 days 
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of R848 treatment. Thus, immunosuppression was not due to a general incapability of B 
cells to produce IgG. 
Splenic lymphoid subpopulations from R848-treated C57BL/6 mice displayed an 
activated phenotype as determined by an increased mean fluorescence intensity of the 
early activation marker CD69 and an increased percentage of CD69-expressing cells (Fig. 
2C and D). The extent of activation was dose-dependent (Fig. 2C). In particular, threefold 
or greater increase in the percentage of CD69+ B220+ B lymphocytes and CD69+ CD8+ T 
cells was detected in C57BL/6 mice treated with 1 mg/kg/d R848 for 7 days. CD69+ 
CD4+ T cells were increased twofold (Fig. 2D). CD69 upregulation was not observed in 
TLR7-/- mice and less pronounced in IFNAR-/- or IRF7-/- mice.  
Effects were not cumulative, because the degree of CD69 upregulation was similar 
after 7, 21, or 42 days. When mice were treated with 0.1 mg/kg/d R848 for 21 and 42 
days, we observed a consistent two- to threefold increase of splenic CD69 expression.  
Thus, our data suggest that sustained triggering of TLR7 induces particular 
lymphocyte activation in secondary lymphoid organs, but prevents an adequate antibody 
response against UV-VSV. 
 
Disruption of the lymphoid structure  
Since efficient immune responses rely on intact lymphoid organs, we investigated the 
splenic follicular and germinal centre microarchitecture upon sustained TLR7 
stimulation. Treatment with 0.1 or 1 mg/kg/d R848 led to malformed and severely 
enlarged white-pulp follicles (Fig. 3). Moreover, sustained TLR7 triggering resulted in a 
dose-dependent hypertrophy of B-cell follicles as well as CD8+ and CD4+ T-cell zones in 
the splenic white pulp (Fig. 3A). Conversely, marginal zone B lymphocytes were 
strongly reduced (B220 and CD21/35; arrowhead). Marginal zone metallophilic MOMA-
1+ macrophages, which appear to play a role in the initial response to systemic 
infection32, and F4/80+ red pulp macrophages, which are extensively involved in the 
clearance of senescent erythrocytes32 were not affected (Fig. 3B). Repetitive treatment 
with PBS, polyI:C or 0.01 mg/kg/d R848 did not induce any derangement of lymphoid 
micro-architecture.  
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Again, the effects detected were likely to be persistent rather than cumulative or 
mitigated. When mice were treated for a longer period (i.e., 21 and 42 days), splenic 
microarchitecture was not further compromised. After 21 and 42 days of 0.01 mg/kg/d 
R848 treatment, spleen microarchitecture was only slightly disturbed, and B- and T-cell 
areas were nearly unaltered, in contrast to a massive enlargement in 0.1 mg/kg R848-
treated mice (Suppl. Figs. 2A/B and 3A/B) that was already evident after 7 days.  
Disruption of the lymphoid structure was TLR7 dependent since TLR7-/- mice 
showed neither disrupted white pulp follicles with enlarged B- and T-cell zones nor 
diminished marginal zone B lymphocytes after 7 days of treatment with 1 mg/kg/d R848 
(Suppl. Fig. 4A/B). IRF7-/- mice had no obvious histopathology, in particular no 
lymphoid follicle malformation. In contrast, IFNAR-/- mice showed some degree of 
inflated follicles with loosened rings of marginal zone B cells (Suppl. Fig. 4A/B), 
indicating that IFNAR and IRF7 signaling partly contributed to R848-mediated 
pathology. 
PNA+ germinal center B-cell clusters and FDC-M1+ follicular dendritic cell-networks 
were reduced upon treatment with 1 mg/kg/d R848 for 7 days (Fig. 3C). PNA+ clusters 
were increased after 21 and, even more pronounced, after 42 days of treatment with 0.1 
mg/kg/d R848, whereas FDC-M1+ cell-networks seemed not to be affected. Flow 
cytometric and RT-PCR analysis confirmed these histological findings: relative 
frequencies of B220/PNA+ and B220/(germinal center B-cell antibody GL7)+ splenocytes 
were reduced after 7 days of TLR7 triggering at 0.1 and 1 mg/kg/d R848 and were 
increased after 21 and 42 days of treatment at 0.1 mg/kg/d R848 (Suppl Fig. 5A). Milk 
fat globule EGF 8 (MFG-E8) mRNA, a marker for follicular dendritic cells33 (FDC), was 
reduced after 7 days of TLR7 triggering at 1 mg/kg/d and unchanged after 21 or 42 days 
of treatment at 0.1 mg/kg/d (Suppl. Fig. 5B). 
 
Expansion of relative frequencies of myeloid cells and a relative contraction of 
lymphoid subsets 
An efficient immune response also requires spatially and temporally orchestrated 
interactions of proper cell types, and this requires organized frequencies and proportions 
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of respective immune cells. We sought to assess splenic immune cell distribution upon 
triggering TLR7. 
After 7 days, spleen weight was 3.3-fold greater in R848-treated than in PBS-treated 
wild-type mice (Fig. 4A). Notably, splenomegaly is found in almost 70% of 
asymptomatic HIV-infected adults34.  Splenomegaly was absent in TLR7-/- mice and less 
pronounced in IFNAR-/- or IRF7-/- mice after R848 treatment,.  
Hyperplasia was probably due to myeloid and possibly due to erythroid expansion in 
the red pulp. Levels of CD11b+ macrophages, CD11c+ dendritic cells (Fig. 4B upper 
panel) and CD11b+/Gr-1+ neutrophils (Fig. 4B lower panel) were increased by about 30-
40% and 100%, respectively, whereas that of lymphoid subpopulations was decreased. 
Relative numbers of B220+ B lymphocytes were reduced by about half as were levels of 
CD4+ and CD8+ T cells (Fig. 4C). Again, reductions were absent in TLR7-/- mice and less 
pronounced in IFNAR-/- or IRF7-/- mice, indicating that the observed effects depend only 
in part on IFNAR and IRF7 signaling (Fig. 4C).  
 
Rapid and long-lasting cytokine deregulation 
TLR7 activation induces an array of cytokines, including IFNs and proinflammatory 
cytokines. Aberrant cytokine production is a hallmark of HIV infection and may 
represent a mode by which HIV induces immunodeficiency. Notably, TNF-α, IL-6, and 
IL-10 levels increase in plasma with kinetics paralleling the raise in plasma viraemia in 
acute HIV infection and are elevated in chronic infection35. Mice treated with 1 mg/kg/d 
R848 for 7 days were analyzed for plasma cytokine levels in a mouse 23-BioPlex 
cytokine assay. IL-10, IL-6, TNF-α, and IL-12p40 were the cytokines that were altered to 
greatest degree (not shown) and therefore investigated in more detail. 
Injection of polyI:C or 0.1 and 1 mg/kg/d R848 resulted in an immediate increase of 
IL-10, IL-6, and TNF-α plasma levels within 90 min, whereas injection of 0.01 mg/kg/d 
R848 had almost no effect (Fig. 5A). Moreover, 1 mg/kg/d R848 resulted in a rapid 
increase of IL-12p40 as measured 6 h after injection (Fig. 5A). IL-10 and IL-12p40 levels 
remained high after several daily injections, respectively. IL-6 and TNF-α levels were 
lower at day 3 than at 90 min, but levels were still higher than in mock-treated mice. 
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Long-term treatment (Fig. 5B) with PBS or 0.01 mg/kg/d R848, again, had no effect, 
whereas IL-10 and TNF-α were permanently elevated upon treatment with 0.1 mg/kg/d. 
IL-6 slowly decreased to almost normal values. IL-12p40 consistently was >1300 pg/ml.  
R848 treatment (7 days, 1 mg/kg/day) of IRF7-/- or IFNAR-/- mice induced IL-10 and 
IL-12p40, but to a lesser degree than in C57BL/6 mice (Fig. 5C). In contrast, TLR7-/- 
mice had normal cytokine levels. In conclusion, the immediate and persistent cytokine 
deregulation by the action of R848 is TLR7 dependent and reminiscent of HIV infection 
in humans. 
 
Induction of thymic hypocellularity 
The thymus is the primary lymphoid organ supplying new T lymphocytes to the 
periphery and might compensate for the loss of T cells caused by HIV. HIV infection, 
however, results in thymic dysfunction and involution that may recover with potent 
antiretroviral therapy36. To investigate whether long-term TLR7 triggering affects thymic 
function, we examined thymus cellularity and the percentage of cells in each thymocyte 
subset by measuring the surface expression of CD4 and CD8 antigens in mice treated 
with 1 mg/kg/day R848 for 7 days. Total thymocytes were reduced 1.9-fold in R848-
treated C57BL/6 mice as compared to mock-treated animals (Fig. 6A). No thymic 
hypocellularity was detected in IFNAR-/-, IRF7-/-, or TLR7-/- mice.  
Flow cytometric analysis of thymocytes from R848-treated mice revealed an increase 
in the prevalence of mature CD4+ and CD8+ single-positive thymocytes from 6.9 to 9.7% 
and 1.9 to 4.5%, respectively, together with a reciprocal reduction in cells that expressed 
both CD4 and CD8 from 79.8 to 72.4% (Fig. 6B). Prevalence of double-negative 
thymocytes was slightly increased, although not significantly. However, in absolute 
numbers, all thymocyte subsets were decreased with the exception of CD8+ single-
positive cells. Absolute reduction of double-positive thymocytes was most prominent.  
 
Immune activation and disruption of the lymphoid system upon systemic and 
repetitive treatment with HIV ssRNA 
HIV encodes multiple TLR7/8 ligands which have a strong MyD88-dependent 
immunostimulatory activity14-16. To substantiate a direct action of HIV ssRNA on 
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immune activation, we used a mixture of HIV ssRNA complexed to DOTAP.  We titrated 
first the HIV ssRNA by examining the activation at 5 h after injection and found 50 µg of 
ssRNA to be optimal for our purposes (data not shown). DOTAP or control ssRNA, in 
which all U nucleotides were replaced with A, had no effect. Mice were then treated daily 
with 50 µg HIV ssRNA for 7 days. HIV ssRNA treatment induced lymphopenia and 
increased relative monocyte and neutrophil numbers in three of four mice (Fig. 7A). 
Moreover, we observed consistent immune activation (Fig. 7B), disruption of the splenic 
structure with malformation of lymphoid follicles and reduced marginal zone B-
lymphocytes (Fig 7C), a relative contraction of CD4+ and CD8+ lymphoid subsets (Fig 
7D), splenomegaly (Fig. 7E), and cytokine deregulation (Fig. 7F). We would like to 
emphasize that the degree of immune dysfunction upon ssRNA or R848 treatment was 
remarkably similar suggesting that HIV may indeed directly contribute to immune 
activation and dysfunction by stimulating TLR7.  
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Discussion 
Chronic immune activation is a major cause for progressive immunodeficiency in HIV 
infection. We used a murine model to assess whether sustained TLR7 stimulation 
contributes to immune activation by studying the effects on the lymphoid system. 
Sustained triggering of TLR7 led to i) altered white blood cell counts, including profound 
lymphopenia and increased neutrophil and monocyte levels ii) immune activation and 
attenuated humoral immune responses, iii) disruption of the lymphoid structure, including 
splenomegaly, enlarged T and B cell zones, reduced marginal zone B-lymphocytes and a 
relative contraction of lymphoid subsets, iv) cytokine deregulation, and v) thymic 
hypocellularity. We also showed that the observed effects were TLR7- and dose 
dependent, and that IRF-7 and IFNAR mediated signaling only partly contributed to 
R848 mediated pathology. Triggering TL7 was done primarily using the synthetic 
compound R848 for practical and financial reasons. Notably, we performed the key 
experiments also using HIV ssRNA as TLR ligand for corroborating the data obtained 
with R848. Very importantly, the effects subsequent to triggering TLR7 by HIV ssRNA 
were similar to the effects with R848 that substantiates their significance for the HIV 
pathogenesis. 
We first monitored blood parameters, because hematological abnormalities are 
common in HIV-infected patients. Repetitive TLR7 triggering resulted in a depletion of 
lymphocytes from the blood together with a reciprocal increase of neutrophils and 
monocytes. This effect was dose dependent and, more importantly, stable as long as 
TLR7 stimulation was maintained. In fact, TLR7 stimulation did not lead to steadily 
increasing amounts of damage or to an attenuated response over time, pointing to the 
possibility that the level of TLR7 signaling over time is a major determinant of the 
observed effects. Of note, individuals with higher HIV RNA levels 6 months after 
seroconversion had faster progression to AIDS37. Blood from R848-treated mice also 
showed a tendency towards lower thrombocyte counts. In HIV infection, the number of 
platelets can be low38 due to trapping of platelets in the enlarged spleen or abnormally 
high levels of TNF-α39, which in fact is released upon TLR7 engagement. Two recent 
studies investigated lymphopenia in acute viral infection and in treatment with a single 
systemic dose of immunomodulatory agents, such as TLR ligands29,40. Our results 
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revealed two net differences: i) lymphocytes but not granulocytes or monocytes were 
depleted from the blood by R848, and ii) lymphopenia was rather specific to TLR7 
activation than an universal phenomenon of TLR triggering, since triggering TLR3 had 
no effect. The latter may be explained by different doses that were applied in the different 
studies. The facts that TLR3 and TLR7 activation both induced similar cytokine patterns, 
but only TLR7 activation induced lymphopenia, also indicate that chronic activation of 
distinct TLRs over time results in characteristic lesions. 
 Gunzer et al. suggested that the R848-induced lymphopenia with its concurrent 
reduction of immune effector cells might lead to immunodeficiency and increased 
susceptibility to infections29. Otherwise, R848 is currently discussed as an effective 
vaccine adjuvant to stimulate humoral immune responses41 since TLR7 ligands directly 
stimulate B cells42. Our observation that sustained TLR7 triggering led to 
immunosuppression with weakened antigen-specific immune responses suggests that 
sustained TLR7 stimulation may be harmful while temporary and time-limited triggering 
may result in antiviral and protective effects. Indeed, guinea pigs infected with Herpes 
simplex virus showed impaired antibody responses upon repetitive TLR7 triggering43.  
The findings that TLR7 triggering stimulated B cells to express an activated 
phenotype and secrete unspecific antibodies indicated that immunosuppression was not 
due to a general incapability of B cells to produce IgG. B-cell activation and 
hypergammaglobulinaemia are characteristic for HIV infection31. The changes in spleen 
morphology and composition subsequent to sustained TLR7 triggering may account for 
the weakened antigen-specific humoral immune response: indeed, the prevalence and 
density of splenic lymphoid subsets was substantially decreased probably due to 
disproportionate myeloid expansion that may result in a dysfunctional microenvironment 
likely underlying the observed immunosuppression.  
Secondary lymphoid organs are the critical place of HIV replication in vivo and HIV 
expression is active throughout the period of asymptomatic HIV infection44 resulting in 
perpetual triggering of TLR7 from the early time point of infection. Sustained TLR7 
triggering caused splenomegaly, follicular hyperplasia, T- and B-cell zones enlargement, 
and a loss of marginal zone B lymphocytes, further emphasizing that sustained TLR7 
triggering may contribute to disease progression in HIV infection. Notably, splenomegaly 
Page 16/34 
is often found in HIV-infected individuals34 and follicular hyperplasia has been reported 
in early-stage disease44. As HIV disease progresses, there is a shift from follicular 
hyperplasia to follicular involution with disruption of the FDC network being 
characteristic during this transition45. Upon R848 treatment for 7 days, FDC networks 
were reduced. At day 21 or 42, however, FDC networks seemed not to be affected. 
Involution might occur after much longer periods of TLR triggering or if higher doses of 
R848 would be applied. Nevertheless, the R848-induced hyperplasia and the loss of intact 
lymphoid tissue architecture may give way to follicular involution, fibrosis, and even 
lymphocyte depletion. Our data also fit with data from a study in lupus-prone mice with a 
translocated copy of TLR7 resulting in a twofold TLR7 expression. These mice develop 
pronounced splenomegaly, increased numbers of activated T cells, and aberrant 
expansion of most immune cell lineages, especially monocytes and neutrophils46. 
TLR7 triggering induced permanently elevated IL-10, IL-6 , and TNF-α levels, which 
also are elevated in chronic HIV infection35. IL-10 may have a crucial role in 
immunoregulation by balancing pathogen-specific immunity and immune-mediated 
tissue damage. Observations from LCMV models have suggested that IL-10 blocking 
strategy may positively affect chronic viral infections, such as HIV or hepatitis C virus 
(HCV) in humans47,48. Similarly, polymorphisms that reduce IL-10 expression have been 
associated with slower progression to AIDS49. Finally, IFN-α and ribavirin, the current 
therapy for HCV, downmodulate IL-10 secretion50. Because IL-6 plays an essential role 
in the differentiation of activated B cells, IL-6 overproduction may contribute to 
polyclonal B-cell activation and to the pathogenesis of AIDS by inducing HIV 
replication51. 
Chronic, low-level TNF expression causes profound disturbances in tissue 
development, especially a diminution of thymic tissue52. In line with these data, R848-
treated mice showed thymic hypocellularity, indicating that TLR7 stimulation may 
damage thymic function and thereby impair the thymus’ capacity to compensate for the 
loss of T cells caused by HIV.  
Indeed, R848 and a mixture of HIV ssRNA oliognucleotides resulted in remarkably 
similar changes in the lymphoid system. We cannot make any firm statements how the 
daily dose of R848 and ssRNA used compares to the viral particle numbers in HIV-
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infected humans. Estimations based on the assumption of ~3x107 HIV DNA+ cells in 
chronically HIV-infected patients may result in >1010 RNA copies with multiple TLR7/8 
motifs every day53; RNA concentrations in tissue reservoirs can even be higher54. 
Notwithstanding, the obvious differences between our model and real HIV infection, the 
data reported propose a potentially very important factor in HIV pathogenesis.  
Using mice deficient for TLR7-/- and MyD88-/- we show that R848-mediated effects 
were dependent upon TLR7 and the adaptor protein MyD88 respectively (Suppl. Fig.6).   
These data are in line with Hemmi’s results that neither MyD88- nor TLR7-deficient 
mice showed any immune activation in response to R84823. Superprofiling of 84 genes 
related to TLR-mediated signal transduction (TLR signaling pathway microarray RT² 
Profiler™ PCR array; Bioscience Corporation) did not reveal any substantial gene 
regulation in TLR7-/- mice that corroborates R848’s exclusive triggering of TLR7. In 
contrast, various TLR signaling related genes were deregulated in splenocytes from wild-
type and IFNAR-/- mice after 1mg/kg/d R848 treatment for 7 days (data not shown). 
Nevertheless, we can not completely exclude off-target effects of R848 with adenosine 
receptors as they were described for imiquimod by Schön et al.55,56. 
  IFNAR and IRF7 signaling only partly contributed to R848-mediated pathology. 
Upon ligand recognition, TLR7 triggers innate immune responses and IFNs through NF-
κB- and IRF7-dependent signaling pathways, respectively57. IRF7 is essential for the 
induction of IFN-α/β genes via the TLR-activated MyD88-dependent pathway24, and 
R848-mediated increases of IFN-α/β directly regulates lymphocyte recirculation and 
causes transient blood lymphopenia40. Although effects upon TLR7 triggering in IFNAR-
/- or IRF7-/- mice were generally less pronounced, they were still present in our mice such 
as lymphopenia. This was unexpected since lymphopenia is critically dependent on 
IFNAR signaling40. Also counterintuitively, we did not see elevated IFN-α levels upon 
repetitive R848 treatment (not shown). Daily dosing with high doses of TLR7 ligands for 
5 consecutive days led to tachyphylaxis: IFNs were almost completely down-regulated58, 
which is normally not seen when doses are separated by more than 2 days. This implies 
that short- and long-term TLR7 activation may have different mechanisms of action.  
In conclusion, our data demonstrate that sustained TLR7 triggering in mice results in 
immune activation and disruption of the lymphoid system reminiscent of HIV-associated 
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pathology. There are differences in the regulation of innate and adaptive immunity 
between men and mice, and thus data obtained in mice need to be interpreted cautiously 
when considering human disease pathology. However, the common main function of 
TLR7 triggering irrespective of cross-species differences20 speaks in favor that HIV 
ssRNA indeed contributes to persistent immune activation and pathology by signaling 
through TLR7 and may explain in part the chronic immune dysfunction in HIV infection. 
Hence, manipulating TLR7 triggering or down-stream signaling may be therapeutically 
valuable to reduce chronic hyper-immune activation and immune dysfunction.  
Page 19/34 
 Acknowledgments  
We thank K. Lang for kindly providing IFNAR-/- and TLR7-/- mice. A. Urwyler (Cytolab, 
Muelligen, Switzerland) is acknowledged for the measurement of serum cytokines. 
 
Conflict-of-interest disclosure: The authors declare no competing financial interests. 
 
Funding: This work was supported by grants from the OPO (Zurich, Switzerland), the 
Roche Research (Basel, Switzerland), and the EMPIRIS Foundation (Zurich, 
Switzerland) to S.B. and R.F.S. 
 
 
Authorship 
Authors’ contribution: S.B. and M.H. designed and performed research, analyzed data, 
and wrote the paper; P.J., E.S., U.H., R.C.M., and S.D. performed research; K.H. 
contributed vital new reagents; T.M.K. and A.A. wrote the paper; R.F.S. designed 
research and wrote the paper. 
 
Page 20/34 
References 
1. Langford SE, Ananworanich J, Cooper DA. Predictors of disease progression in HIV 
infection: a review. AIDS Res Ther. 2007;4:11. 
2. Silvestri G, Sodora DL, Koup RA, et al. Nonpathogenic SIV infection of sooty mangabeys is 
characterized by limited bystander immunopathology despite chronic high-level viremia. 
Immunity. 2003;18:441-452. 
3. Wu L, Paxton WA, Kassam N, et al. CCR5 levels and expression pattern correlate with 
infectability by macrophage-tropic HIV-1, in vitro. J Exp Med. 1997;185:1681-1691. 
4. Kang SM, Tran AC, Grilli M, Lenardo MJ. NF-kappa B subunit regulation in 
nontransformed CD4+ T lymphocytes. Science. 1992;256:1452-1456. 
5. Shattock RJ, Rizzardi GP, Hayes P, Griffin GE. Engagement of adhesion molecules (CD18, 
CD11a, CD45, CD44, and CD58) enhances human immunodeficiency virus type 1 
replication in monocytic cells through a tumor necrosis factor-modulated pathway. J Infect 
Dis. 1996;174:54-62. 
6. Tesselaar K, Arens R, van Schijndel GM, et al. Lethal T cell immunodeficiency induced by 
chronic costimulation via CD27-CD70 interactions. Nat Immunol. 2003;4:49-54. 
7. Schindler M, Munch J, Kutsch O, et al. Nef-mediated suppression of T cell activation was 
lost in a lentiviral lineage that gave rise to HIV-1. Cell. 2006;125:1055-1067. 
8. Smith SM. The pathogenesis of HIV infection: stupid may not be so dumb after all. 
Retrovirology. 2006;3:60. 
9. Swingler S, Mann A, Jacque J, et al. HIV-1 Nef mediates lymphocyte chemotaxis and 
activation by infected macrophages. Nat Med. 1999;5:997-103. 
10. Cicala C, Arthos J, Selig SM, et al. HIV envelope induces a cascade of cell signals in non-
proliferating target cells that favor virus replication. Proc Natl Acad Sci U S A. 
2002;99:9380-9385. 
11. Eggena MP, Barugahare B, Jones N, et al. Depletion of regulatory T cells in HIV infection is 
associated with immune activation. J Immunol. 2005;174:4407-4414. 
12. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376. 
13. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic 
immune activation in chronic HIV infection. Nat Med. 2006;12:1365-1371. 
14. Meier A, Alter G, Frahm N, et al. MyD88-dependent immune activation mediated by human 
immunodeficiency virus type 1-encoded toll-like receptor ligands. J Virol. 2007;81:8180-
8191. 
15. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA 
via toll-like receptor 7 and 8. Science. 2004;303:1526-1529. 
16. Beignon AS, McKenna K, Skoberne M, et al. Endocytosis of HIV-1 activates plasmacytoid 
dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest. 2005;115:3265-
3275. 
17. Lester RT, Yao XD, Ball TB, et al. Toll-like receptor expression and responsiveness are 
increased in viraemic HIV-1 infection. Aids. 2008;22:685-694. 
18. Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, Lederman MM. Toll-Like 
Receptor Ligands Induce Human T Cell Activation and Death, a Model for HIV 
Pathogenesis. PLoS ONE. 2008;3:e1915. 
19. Schlaepfer E, Audige A, Joller H, Speck RF. TLR7/8 triggering exerts opposing effects in 
acute versus latent HIV infection. J Immunol. 2006;176:2888-2895. 
Page 21/34 
20. Diebold SS. Recognition of viral single-stranded RNA by Toll-like receptors. Adv Drug 
Deliv Rev. 2008;60:813-823. 
21. Gorden KK, Qiu XX, Binsfeld CC, Vasilakos JP, Alkan SS. Cutting edge: activation of 
murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT 
oligodeoxynucleotides. J Immunol. 2006;177:6584-6587. 
22. Muller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interferons in 
antiviral defense. Science. 1994;264:1918-1921. 
23. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells 
via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196-200. 
24. Honda K, Yanai H, Negishi H, et al. IRF-7 is the master regulator of type-I interferon-
dependent immune responses. Nature. 2005;434:772-777. 
25. Adachi O, Kawai T, Takeda K, et al. Targeted disruption of the MyD88 gene results in loss 
of IL-1- and IL-18-mediated function. Immunity. 1998;9:143-150. 
26. Bachmann MF, Odermatt B, Hengartner H, Zinkernagel RM. Induction of long-lived 
germinal centers associated with persisting antigen after viral infection. J Exp Med. 
1996;183:2259-2269. 
27. Karrer U, Lopez-Macias C, Oxenius A, et al. Antiviral B cell memory in the absence of 
mature follicular dendritic cell networks and classical germinal centers in TNFR1-/- mice. J 
Immunol. 2000;164:768-778. 
28. Fieller EC. Suppl to JRStatistSoc;7:1-64. 
29. Gunzer M, Riemann H, Basoglu Y, et al. Systemic administration of a TLR7 ligand leads to 
transient immune incompetence due to peripheral-blood leukocyte depletion. Blood. 
2005;106:2424-2432. 
30. Kaslow RA, Phair JP, Friedman HB, et al. Infection with the human immunodeficiency 
virus: clinical manifestations and their relationship to immune deficiency. A report from the 
Multicenter AIDS Cohort Study. Ann Intern Med. 1987;107:474-480. 
31. De Milito A, Nilsson A, Titanji K, et al. Mechanisms of hypergammaglobulinemia and 
impaired antigen-specific humoral immunity in HIV-1 infection. Blood. 2004;103:2180-
2186. 
32. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S. Macrophage 
receptors and immune recognition. Annu Rev Immunol. 2005;23:901-944. 
33. Kranich J, Krautler NJ, Heinen E, et al. Follicular dendritic cells control engulfment of 
apoptotic bodies by secreting Mfge8. J Exp Med. 2008;205:1293-1302. 
34. Furrer H. Prevalence and clinical significance of splenomegaly in asymptomatic human 
immunodeficiency virus type 1-infected adults. Swiss HIV cohort study. Clin Infect Dis. 
2000;30:943-945. 
35. Norris PJ, Pappalardo BL, Custer B, Spotts G, Hecht FM, Busch MP. Elevations in IL-10, 
TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res 
Hum Retroviruses. 2006;22:757-762. 
36. Ye P, Kirschner DE, Kourtis AP. The thymus during HIV disease: role in pathogenesis and 
in immune recovery. Curr HIV Res. 2004;2:177-183. 
37. Geskus RB, Prins M, Hubert JB, et al. The HIV RNA setpoint theory revisited. 
Retrovirology. 2007;4:65. 
38. Ballem PJ, Belzberg A, Devine DV, et al. Kinetic studies of the mechanism of 
thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med. 
1992;327:1779-1784. 
Page 22/34 
39. Tacchini-Cottier F, Vesin C, Redard M, Buurman W, Piguet PF. Role of TNFR1 and TNFR2 
in TNF-induced platelet consumption in mice. J Immunol. 1998;160:6182-6186. 
40. Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. Type I interferons directly regulate 
lymphocyte recirculation and cause transient blood lymphopenia. Blood. 2006. 
41. Fransen F, Boog CJ, van Putten JP, van der Ley P. Agonists of Toll-like receptor 3, 4, 7, and 
9 are adjuvant candidates for use in an outer membrane vaccine against Neisseria 
meningitidis serogroup B. Infect Immun. 2007. 
42. Bishop GA, Ramirez LM, Baccam M, Busch LK, Pederson LK, Tomai MA. The immune 
response modifier resiquimod mimics CD40-induced B cell activation. Cell Immunol. 
2001;208:9-17. 
43. Bernstein DI, Harrison CJ, Tomai MA, Miller RL. Daily or weekly therapy with resiquimod 
(R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and 
after treatment. J Infect Dis. 2001;183:844-849. 
44. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in 
lymphoid tissue during the clinically latent stage of disease. Nature. 1993;362:355-358. 
45. Cohen OJ, Pantaleo G, Lam GK, Fauci AS. Studies on lymphoid tissue from HIV-infected 
individuals: implications for the design of therapeutic strategies. Springer Semin 
Immunopathol. 1997;18:305-322. 
46. Subramanian S, Tus K, Li QZ, et al. A Tlr7 translocation accelerates systemic autoimmunity 
in murine lupus. Proc Natl Acad Sci U S A. 2006;103:9970-9975. 
47. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-
10 determines viral clearance or persistence in vivo. Nat Med. 2006;12:1301-1309. 
48. Ejrnaes M, Filippi CM, Martinic MM, et al. Resolution of a chronic viral infection after 
interleukin-10 receptor blockade. J Exp Med. 2006;203:2461-2472. 
49. Shin HD, Winkler C, Stephens JC, et al. Genetic restriction of HIV-1 pathogenesis to AIDS 
by promoter alleles of IL10. Proc Natl Acad Sci U S A. 2000;97:14467-14472. 
50. Accapezzato D, Francavilla V, Paroli M, et al. Hepatic expansion of a virus-specific 
regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest. 
2004;113:963-972. 
51. Rosenberg ZF, Fauci AS. Immunopathogenic mechanisms of HIV infection: cytokine 
induction of HIV expression. Immunol Today. 1990;11:176-180. 
52. Glosli H, Prydz H, Roald B. Involution of thymus and lymphoid depletion in mice 
expressing the hTNF transgene. Apmis. 2004;112:63-73. 
53. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body 
viral load in HIV-1 infection. Nature. 1997;387:183-188. 
54. Haase AT, Henry K, Zupancic M, et al. Quantitative image analysis of HIV-1 infection in 
lymphoid tissue. Science. 1996;274:985-989. 
55. Schon MP, Schon M, Klotz KN. The small antitumoral immune response modifier 
imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent 
fashion. J Invest Dermatol. 2006;126:1338-1347. 
56. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene. 2008;27:190-
199. 
57. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. 
Nat Rev Immunol. 2007;7:179-190. 
58. Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomai MA. Cytokine induction in mice by 
the immunomodulator imiquimod. J Leukoc Biol. 1994;55:234-240. 
Page 23/34 
Figure Legends 
Figure 1. Sustained TLR7 stimulation induces lymphopenia and increased 
neutrophil and monocyte numbers. (A–D) Mice were treated with the TLR7 ligand 
R848 in a daily fashion. After 7 days of treatment, blood was analyzed for the presence of 
leukocytes, lymphocytes, monocytes, neutrophils, and thrombocytes 1 h after the last 
injection. (A) R848 treatment did not affect absolute numbers of circulating leukocytes. 
Left: 1 mg R848/kg/day; analysis by flow cytometry before and after treatment. Numbers 
signify percentage of viable leukocytes as determined by FSC/SSC characteristics. 
Arrowhead indicates monocytes and neutrophils (i.e., large granular cells with high 
FSC/SSC properties). Right: analysis by hemocounter. (B) Total lymphocytes and all 
major lymphocytic cellular subsets (i.e., B220+ B cells, CD4+, and CD8+ T cells) were 
massively decreased, whereas (C) monocyte and neutrophil numbers increased. Effects 
are dose- and TLR7 dependent. Lymphocyte, monocytes and neutrophils numbers were 
determined mechanically; absolute numbers of lymphocyte subpopulations were 
determined using BD truCOUNT technology. (D) Thrombocyte numbers were 
determined with hemocounter. (E) Similar analysis after 21 days of TLR7 stimulation. 
Error bars indicate standard error. Data of at least three individually measured animals 
are shown. pIC = polyI:C. 
 
Figure 2. Sustained TLR7 triggering results in a weakened antigen-specific humoral 
immune response despite immune activation. (A) Attenuation of humoral immune 
response after treatment with UV-VSV. Mice were treated with PBS or 1 mg/kg/day 
R848 for 7 days and subsequently immunized with UV-VSV. Neutralizing IgM and IgG 
titers were monitored for the following 20 days. Means from mock- and R848-treated 
animals were compared using unpaired t-test. N=5. (B) Immunosuppression is not due to 
a general incapability of B cells to produce IgG. Total IgG levels were measured at day 0, 
after treatment with 1 mg/kg/day R848 for 7 and 20 days after UV-VSV inoculation. 
Means were compared using paired t-test. N ≥ 5. (C–D) Splenic lymphoid subpopulations 
from R848-treated animals displayed an activated phenotype after 7 days of treatment. 
Receptor expression was analyzed by flow cytometry. (C) Dose-dependent increase of 
CD69 mean fluorescence intensity on B220+ B cells. Grey and black lines indicate cells 
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stained with isotype or specific monoclonal Antibody, respectively. One representative 
mouse from each group is shown. (D) TLR7-dependent increase in the percentage of 
lymphoid subsets expressing CD69. Error bars indicate standard error. N ≥ 5. 
 
Figure 3. Disruption of the lymphoid structure after 7 days of sustained TLR7 
stimulation. Spleen cyrosections of C57BL/6 mice treated for 7 days with R848. (A) 
Applied dose correlated with malformation of splenic lymphoid follicles with enlarged T- 
(CD4 and CD8) and B- (B220) cell zones, and reduced marginal zone B lymphocytes 
(B220 and CD21/35; arrowhead). (B) MOMA-1+ and F4/80+ macrophages were not 
affected. (C) PNA+ germinal centres (arrowheads) and FDC-M1+ networks were reduced 
at day 7 but not at day 21 or 42 of treatment. R848 concentrations were as indicated 
(mg/kg/day). N ≥ 3. 
 
Figure 4. Splenomegaly is associated with an expansion of relative frequencies of 
myeloid cells and a relative contraction of lymphoid subsets. (A) Splenomegaly is 
dose- and TLR7-dependent. Splenomegaly was less pronounced in IFNAR-/- or IRF7-/- 
mice and absent in TLR7-/- mice upon 1 mg/kg/day of R848 treatment. Spleen weight was 
first normalized to total body weight of each individual mouse and, second, normalized to 
the spleen weight of mock-treated animals. Error bars indicate 95% confidence intervals. 
(B) The prevalence of CD11b+ macrophages, CD11c+ dendritic cells and CD11b+/Gr-1+ 
neutrophils was increased, whereas that of lymphoid subpopulations was decreased as 
compared to mock-treated animals (C). Mice were treated with PBS or 1 mg/kg/day R848 
for 7 days. Splenocytes were stained with indicated antibodies and relative numbers were 
assessed by flow cytometry. Error bars indicate standard error. N ≥ 3. 
 
Figure 5. Rapid and long-lasting cytokine deregulation upon triggering TLR7. Mice 
were bled from the tail vein, and cytokine levels were measured using a multiplexed 
particle-based flow cytometric cytokine assay. (A) Rapid cytokine deregulation. Cytokine 
levels were measured before (baseline, BL), 90 min after the first injection, and on day 3 
of repetitive treatment. IL-12p40 levels were measured 6 h after a single dose and on day 
7 of repetitive treatment. (B) Long-lasting cytokine deregulation. Mice were treated daily 
Page 25/34 
at indicated concentrations, and cytokine levels were monitored over time (i.e., on day 7, 
21, and 42 of treatment). (C) Cytokine deregulation is TLR7 dependent. C57BL/6 and 
knockout mice were treated with 1 mg/kg/day of R848 for 7 days. Cytokine levels at day 
0 (left bars) and at day 7 (right bars) are shown. Mean values from mock- and R848-
treated animals at analogous time points were compared using unpaired t-test. Error bars 
indicate standard error. N ≥ 3. 
 
Figure 6. Thymic hypocellularity upon triggering TLR7. Mice were treated with PBS 
or 1 mg/kg/day of R848 for 7 days. (A) Thymus was hypocellular in C57BL/6 mice but 
not in knockout mice upon treatment with R848. Thymocytes were counted manually and 
normalized to total thymocyte counts of the corresponding mock-treated animals. Error 
bars indicate 95% confidence intervals. (B) Relative cell numbers in each thymocyte 
subset were measured in C57BL/6 mice by staining for CD4 and CD8, followed by flow 
cytometric analysis. Error bars indicate standard error. For C57BL/6 animals data from 
three independent experiments, each with N = 3, were pooled; N = 3 for knockout mice. 
 
Figure 7. Immune activation and lymphoid system disruption upon HIV ssRNA 
treatment. Mice were treated i.v. with a mixture of uridine-rich HIV ssRNA (RNA U, 50 
µg/mouse/d) or control RNA (RNA A) for 7 days. (A) HIV ssRNA treatment induced 
lymphopenia and increased relative monocyte and neutrophil numbers in three of four 
mice. Blood was analyzed 1 h after the last injection. (B) Splenic lymphoid 
subpopulations from ssRNA-treated animals displayed an activated phenotype. CD69 
expression was analyzed by flow cytometry. (C) Disruption of the lymphoid structure 
upon ssRNA treatment. There was malformation of splenic lymphoid follicles (CD4 and 
not shown), and reduced marginal zone B lymphocytes (CD21/35; arrowhead). (D) 
Relative contraction of CD4+ and CD8+ lymphoid subsets upon ssRNA treatment. 
Splenocytes were stained with indicated antibodies and relative numbers were assessed 
by flow cytometry. (E) Splenomegaly upon ssRNA treatment. Spleen weight was first 
normalized to total body weight and, second, normalized to the spleen weight of mock-
treated animals. Error bars indicate 95% confidence intervals. (F) Cytokine deregulation 
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upon ssRNA treatment. Cytokine levels at day 7 are shown. Error bars indicate standard 
error. N = 4 for ssRNA treated mice. 
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Supplementary Methods 
 
MFG-E8 RT-PCR 
Splenic samples were immediately subjected to RNAlater (Qiagen) and stored at -20 °C until 
use. RNA was extracted from 20 mg of samples with the RNeasy mini-kit (Qiagen) according 
to the manufacturer’s instructions. For tissue homogenates, blocks were disrupted with a 
mortar and pestle in lysis buffer containing 2-ME. After extraction, RNA was pooled from 
replicates (N = 3). To remove residual DNA, RNA preparations were treated with DNAfree 
(Ambion) according to the manufacturer’s instructions. RNA quality, as judged by gel 
electrophoresis and spectrophotometry, was comparable in all samples. Reverse transcription 
was performed with 5 µg  of total RNA in a total volume of 50 µl. RNA was incubated with 
1250 ng of oligo(dT) primer (Life Technologies) and 500 µM dNTPs (Roche) at 65°C for 5 
min, followed by incubation on ice for 5 min. Samples were then incubated with 3 mM MgCl2 
(Promega) and 60 U of RNase inhibitor (Roche) in 1x ImProm-II RT reaction buffer 
(Promega) at 42°C for 2 min. ImProm-II RT (500 U; Promega) was added, and reactions were 
performed at 42°C for 50 min, followed by inactivation at 65°C for 15 min. Residual RNA 
was digested with 1250 ng of RNase (Roche) at 37°C for 20 min.  
RT-PCR was performed using an ABI Prism 7700 sequence detection system (Applied 
Biosystems) with conditions as mentioned above. MFG-E8 mRNA, representative of 
follicular dendritic cell marker FDC-M1, and GAPDH housekeeping gene were detected 
using ready-to-use primer/probe kits (Applied Biosystems; Mm00500549_m1 and 
Mm99999915_g1). All reactions were performed in triplicate. Data were analyzed in two 
steps. First, the mean normalized gene expression (MNE) for every sample was determined 
using the software application Q-Gene (calculation procedure for MNE 2) 1. Second, 
normalized MFG-E8 expression, relative to that of respective Mock treated mice was 
assessed. 
 
1. Muller PY, Janovjak H, Miserez AR, Dobbie Z. Processing of gene expression data 
generated by quantitative real-time RT-PCR. Biotechniques. 2002;32:1372-1374, 1376, 
1378-1379. 
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Supplementary Figure 1. R848-induced lymphopenia and increased neutrophil and 
monocyte numbers are TLR7 dependent. 
Mice were treated with 1 mg/kg/d R848 for 7 days. Blood lymphocytes, monocytes, 
neutrophils, and thrombocytes numbers were determined with a hemocounter one hour after 
the last injection. Effects are TLR7 dependent but IFNAR and IRF 7 signaling seems not to be 
critically involved because effects in R848-treated mice lacking IFNAR or IRF7 were similar 
as in wild-type mice. Data of at least 3 individually measured animals are shown but IFNAR-/- 
thrombocyte counts (#) where only 2 animals are shown. 
 
Supplementary Figure 2. Disruption of the lymphoid structure is not further 
compromised after 21 days of chronic TLR7 stimulation. 
(A) Spleen cryosections of C57BL/6 mice showing a dose dependent malformation of 
lymphoid follicles with enlarged T and B-cell zones, and reduced marginal zone B 
lymphocytes. Lymphoid disruption was not further compromised after 21 days of treatment as 
compared to the 7 day-treatment (see also Figure 3). (B) MOMA-1+ and F4/80+ macrophages 
were not affected.  N ≥ 3. 
 
Supplementary Figure 3. Disruption of the Lymphoid Structure is not further 
compromised even after 42 days of chronic TLR7 stimulation. 
(A-B) See legend Supplementary Figure 2 for details.  
 
Supplementary Figure 4. Disruption of the Lymphoid Structure is TLR7 dependent. 
(A) Spleen cryosections of C57BL/6, TLR7-/-, IFNAR-/- and IRF7-/- mice after 7 days of 
treatment with 1 mg/kg/d R848, showing a TLR7 dependent malformation of splenic 
lymphoid follicles since TLR7-/- mice showed normal T- and B-cell zones as well as unaltered 
marginal zone B-lymphocyte rings. IRF7 knockout mice showed no obvious symptoms of 
lymphoid follicle malformation. In contrast, IFNAR-/- mice showed somewhat inflated 
follicles with loosened rings of marginal zone B cells. (B) MOMA-1+ and F4/80+ 
macrophages as well as FDC-M1 networks and PNA+ germinal centres (data not shown) were 
not affected. N ≥ 3. 
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Supplementary Figure 5. Germinal center B cells and MFG-E8 mRNA are decreased at 
day 7 and increased or unaffected at day 21/42 of repetitive TLR7 triggering. 
(A) C57BL/6 mice were treated as indicated. Splenic germinal center B-cell frequencies were 
evaluated by flow cytometry by staining for B220 in conjunction with FITC-labeled PNA 
(upper panel) or GL7 antibody (lower panel). Percentage of double positive cells was 
normalized to that of corresponding mock treated animals. Error bars indicate 95% confidence 
intervals. N ≥ 3. (B) RNA was extracted from spleen (N = 3), pooled for reverse transcription 
and analyzed for MFG-E8 transcripts (see Supplementary Methods). Mean normalized MFG-
E8 expression was calibrated to the matching mock control. Error bars indicate SEM of mean 
normalized expression relative to calibrator.  
 
Supplementary Figure 6. Immune activation and lymphoid system disruption is MyD88 
dependent. 
MyD88-/- mice were treated with 1mg/kg/d R848 for 7 days. (A) Blood was analyzed for the 
presence of lymphocytes, monocytes, and neutrophiles 1 h after the last injection. There was a 
tendency towards a slight lymphopenia and increased neutrophile numbers in MyD88-/- mice, 
although this was not statistically significant. Monocyte numbers were increased. This 
suggests some MyD88/TLR independent mechanisms. However, white blood cell counts were 
not altered in TLR7-/- animals (Fig. 1 and Suppl. Fig 1). (B) Increase in the percentage of 
lymphoid subsets expressing CD69 is MyD88 dependent. Splenic lymphoid subpopulations 
from R848-treated MyD88-/- animals displayed no activated phenotype. CD69 expression was 
analyzed by flow cytometry. (C) Disruption of the lymphoid structure is MyD88 dependent. 
There was no malformation of splenic lymphoid follicles with enlarged T- (CD4) and B-cell 
zones (not shown), and reduced marginal zone B lymphocytes (CD21/35; arrowhead) in 
MyD88-/- mice. (D) Relative contraction of lymphoid subsets in spleen is MyD88 dependent. 
Splenocytes were stained with indicated antibodies and relative numbers were assessed by 
flow cytometry. (E) Splenomegaly is MyD88 dependent. Spleen weight was first normalized 
to total body weight and, second, normalized to the spleen weight of mock-treated animals. 
Error bars indicate 95% confidence intervals. (F) Cytokine deregulation is MyD88 dependent. 
Cytokine levels at day 7 are shown. TNF-α, IL-6, and IL-1β levels in MyD88-/- were below 
detection limit (0.8, 0.8, and 0.3 pg/ml, respectively). Error bars indicate standard error. N ≥ 
3. 
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Supplementary Figure 5 
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Supplementary Figure 5. Germinal center B cells and MFG-E8 mRNA are decreased at 
day 7 and increased or unaffected at day 21/42 of repetitive TLR7 triggering. 
(A) C57BL/6 mice were treated as indicated. Splenic germinal center B-cell frequencies were 
evaluated by flow cytometry by staining for B220 in conjunction with FITC-labeled PNA 
(upper panel) or GL7 antibody (lower panel). Percentage of double positive cells was 
normalized to that of corresponding mock treated animals. Error bars indicate 95% confidence 
intervals. N ≥ 3. (B) RNA was extracted from spleen (N = 3), pooled for reverse transcription 
and analyzed for MFG-E8 transcripts (see Supplementary Methods). Mean normalized MFG-
E8 expression was calibrated to the matching mock control. Error bars indicate SEM of mean 
normalized expression relative to calibrator.  
 
Supplementary Figure 6. Immune activation and lymphoid system disruption is MyD88 
dependent. 
MyD88-/- mice were treated with 1mg/kg/d R848 for 7 days. (A) Blood was analyzed for the 
presence of lymphocytes, monocytes, and neutrophiles 1 h after the last injection. There was a 
tendency towards a slight lymphopenia and increased neutrophile numbers in MyD88-/- mice, 
although this was not statistically significant. Monocyte numbers were increased. This 
suggests some MyD88/TLR independent mechanisms. However, white blood cell counts were 
not altered in TLR7-/- animals (Fig. 1 and Suppl. Fig 1). (B) Increase in the percentage of 
lymphoid subsets expressing CD69 is MyD88 dependent. Splenic lymphoid subpopulations 
from R848-treated MyD88-/- animals displayed no activated phenotype. CD69 expression was 
analyzed by flow cytometry. (C) Disruption of the lymphoid structure is MyD88 dependent. 
There was no malformation of splenic lymphoid follicles with enlarged T- (CD4) and B-cell 
zones (not shown), and reduced marginal zone B lymphocytes (CD21/35; arrowhead) in 
MyD88-/- mice. (D) Relative contraction of lymphoid subsets in spleen is MyD88 dependent. 
Splenocytes were stained with indicated antibodies and relative numbers were assessed by 
flow cytometry. (E) Splenomegaly is MyD88 dependent. Spleen weight was first normalized 
to total body weight and, second, normalized to the spleen weight of mock-treated animals. 
Error bars indicate 95% confidence intervals. (F) Cytokine deregulation is MyD88 dependent. 
Cytokine levels at day 7 are shown. TNF-α, IL-6, and IL-1β levels in MyD88-/- were below 
detection limit (0.8, 0.8, and 0.3 pg/ml, respectively). Error bars indicate standard error. N ≥ 
3. 
 
